OncoTherapy Science Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Junichi Shimada

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	8.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Junichi Shimada (63 yo)

2.3yrs

Görev süresi

Mr. Junichi Shimada is President, Chief Executive Officer of OncoTherapy Science, Inc. since July 2022 and serves as its Director from June 2022.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hatsuo Kato	Executive Chairman	47.6yrs	Veri yok	Veri yok
Junichi Shimada	President	2.4yrs	Veri yok	Veri yok
Jae-Hyun Park	Chief Scientific Officer & Director	6.4yrs	Veri yok	Veri yok
Yuichi Komine	Independent External Director	10.2yrs	Veri yok	Veri yok
Miyako Takagi	External Auditor	20.4yrs	Veri yok	0.011% € 6.2k
Teruhisa Tajima	External Auditor	10.2yrs	Veri yok	Veri yok
Yuka Yamane	Auditor	3.4yrs	Veri yok	0.018% € 10.0k
Yoshio Miki	Independent External Director	2.4yrs	Veri yok	Veri yok

8.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 30O 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).

OncoTherapy Science Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022

Recent updates

Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)

OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024

New major risk - Financial data availability

First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)

OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)

OncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024

OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor

Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)

OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)

OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)

OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Shareholder dilution

New major risk - Share price stability

Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)

OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023

Less than half of directors are independent

Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)

OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)

OncoTherapy Science, Inc. to Report Q2, 2023 Results on Nov 04, 2022

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)

OncoTherapy Science, Inc. to Report Q1, 2023 Results on Aug 05, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc. to Report Fiscal Year 2022 Results on May 06, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

OncoTherapy Science, Inc. to Report Q3, 2022 Results on Feb 04, 2022

Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm

OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding

Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)

OncoTherapy Science, Inc. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: €0.83

New 90-day low: €0.96

Second quarter 2021 earnings released: JP¥2.48 loss per share

New 90-day high: €1.47

OncoTherapy Science, Inc. to Report Q1, 2021 Results on Aug 07, 2020

First quarter earnings released

First quarter earnings released

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş